nach oben

Erschienen in:

05.07.2022 | Preclinical study

Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer

verfasst von: Lili Chen, Yanyang Chen, Zhongpeng Xie, Jiao Luo, Yuefeng Wang, Jianwen Zhou, Leilei Huang, Hongxia Li, Linhai Wang, Pei Liu, Man Shu, Wenhui Zhang, Zunfu Ke

Erschienen in: Breast Cancer Research and Treatment | Ausgabe 3/2022

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Currently, the most commonly applied method for the determination of breast cancer subtypes is to test estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (HER2), and Ki67 by immunohistochemistry (IHC). However, the IHC method has substantial intraobserver and interobserver variability. ESR1, PGR, ERBB2, and MKi67 mRNA tests by reverse transcription-quantitative polymerase chain reaction (RT-qPCR) assay may improve the diagnostic objectivity and efficiency. Here, we compared the concordance between RT-qPCR and IHC for assessment of the same biomarkers and evaluated the subtypes.

Methods

A total of 265 eligible cases were divided into a training cohort and a validation cohort, and the expressions of ER/ESR1, PR/PGR, HER2/ERBB2, and Ki67/MKI67 were tested by IHC and RT-qPCR. Then, the appropriate cutoff of RT-qPCR was calculated in the training cohort. The concordance between RT-qPCR and IHC was calculated for individual marker. In addition, we investigated the subtypes based on the RT-qPCR results.

Results

The Spearman correlation coefficients between ER/ESR1, PR/PGR, HER2/ERBB2, and Ki67/MKI67 by IHC and RT-qPCR were 0.768, 0.699, 0.762, and 0.387, respectively. The cutoff values for the RT-qPCR assay of ESR1 (1%), PGR (1%), ERBB2, and MKi67 (14%) were 35.539, 32.139, 36.398, and 29.176, respectively. The overall percent agreement (OPA) between ER/ESR1, PR/PGR, HER2/ERBB2, and Ki67/MKI67 by IHC and RT-qPCR was 92.48%, 73.68%, 92.80%, and 74.44%, respectively. A total of 224 (84.53%) specimens were concordant for the breast cancer subtypes (IHC-based type) by RT-qPCR.

Conclusion

Evaluation of breast cancer biomarker status by RT-qPCR was highly concordant with IHC. RT-qPCR can be used as a supplementary method to detect molecular markers of breast cancer.

Nur mit Berechtigung zugänglich

Siegel RL, Miller KD, Fuchs HE, Jemal A (2021) Cancer statistics, 2021. CA Cancer J Clin 71(1):7–33. https://doi.org/10.3322/caac.21654CrossRefPubMed

Spoerke JM, Gendreau S, Walter K, Qiu J, Wilson TR, Savage H et al (2016) Heterogeneity and clinical significance of ESR1 mutations in ER-positive metastatic breast cancer patients receiving fulvestrant. Nat Commun 7:11579. https://doi.org/10.1038/ncomms11579CrossRefPubMedPubMedCentral

Jackson HW, Fischer JR, Zanotelli VRT, Ali HR, Mechera R, Soysal SD et al (2020) The single-cell pathology landscape of breast cancer. Nature 578(7796):615–620. https://doi.org/10.1038/s41586-019-1876-xCrossRefPubMed

Liang Y, Zhang H, Song X, Yang Q (2020) Metastatic heterogeneity of breast cancer: molecular mechanism and potential therapeutic targets. Semin Cancer Biol 60:14–27. https://doi.org/10.1016/j.semcancer.2019.08.012CrossRefPubMed

Coates AS, Winer EP, Goldhirsch A, Gelber RD, Gnant M, Piccart-Gebhart M et al (2015) Tailoring therapies–improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015. Ann Oncol 26(8):1533–1546. https://doi.org/10.1093/annonc/mdv221CrossRefPubMedPubMedCentral

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA et al (2000) Molecular portraits of human breast tumours. Nature 406(6797):747–752. https://doi.org/10.1038/35021093CrossRefPubMed

Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL et al (2020) Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol 38(12):1346–1366. https://doi.org/10.1200/jco.19.02309CrossRefPubMed

Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS et al (2018) Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists Clinical practice guideline focused update. J Clin Oncol 36(20):2105–2122. https://doi.org/10.1200/jco.2018.77.8738CrossRefPubMed

Nielsen TO, Leung SCY, Rimm DL, Dodson A, Acs B, Badve S et al (2021) Assessment of Ki67 in breast cancer: updated recommendations from the international Ki67 in Breast Cancer Working Group. J Natl Cancer Inst 113(7):808–819. https://doi.org/10.1093/jnci/djaa201CrossRefPubMed

10.

Lee M, Lee CS, Tan PH (2013) Hormone receptor expression in breast cancer: postanalytical issues. J Clin Pathol 66(6):478–484. https://doi.org/10.1136/jclinpath-2012-201148CrossRefPubMed

11.

Orlando L, Viale G, Bria E, Lutrino ES, Sperduti I, Carbognin L et al (2016) Discordance in pathology report after central pathology review: Implications for breast cancer adjuvant treatment. Breast 30:151–155. https://doi.org/10.1016/j.breast.2016.09.015CrossRefPubMed

12.

Reisenbichler ES, Lester SC, Richardson AL, Dillon DA, Ly A, Brock JE (2013) Interobserver concordance in implementing the 2010 ASCO/CAP recommendations for reporting ER in breast carcinomas: a demonstration of the difficulties of consistently reporting low levels of ER expression by manual quantification. Am J Clin Pathol 140(4):487–494. https://doi.org/10.1309/ajcp1rf9fuizrdpiCrossRefPubMed

13.

Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF et al (2015) Prospective validation of a 21-gene expression assay in breast cancer. N Engl J Med 373(21):2005–2014. https://doi.org/10.1056/NEJMoa1510764CrossRefPubMedPubMedCentral

14.

Knauer M, Mook S, Rutgers EJ, Bender RA, Hauptmann M, van de Vijver MJ et al (2010) The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer. Breast Cancer Res Treat 120(3):655–661. https://doi.org/10.1007/s10549-010-0814-2CrossRefPubMed

15.

Wallden B, Storhoff J, Nielsen T, Dowidar N, Schaper C, Ferree S et al (2015) Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Med Genom 8:54. https://doi.org/10.1186/s12920-015-0129-6CrossRef

16.

Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B et al (2013) Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of early breast cancer 2013. Ann Oncol 24(9):2206–2223. https://doi.org/10.1093/annonc/mdt303CrossRefPubMedPubMedCentral

17.

Wirtz RM, Sihto H, Isola J, Heikkilä P, Kellokumpu-Lehtinen PL, Auvinen P et al (2016) Biological subtyping of early breast cancer: a study comparing RT-qPCR with immunohistochemistry. Breast Cancer Res Treat 157(3):437–446. https://doi.org/10.1007/s10549-016-3835-7CrossRefPubMedPubMedCentral

18.

Wu NC, Wong W, Ho KE, Chu VC, Rizo A, Davenport S et al (2018) Comparison of central laboratory assessments of ER, PR, HER2, and Ki67 by IHC/FISH and the corresponding mRNAs (ESR1, PGR, ERBB2, and MKi67) by RT-qPCR on an automated, broadly deployed diagnostic platform. Breast Cancer Res Treat 172(2):327–338. https://doi.org/10.1007/s10549-018-4889-5CrossRefPubMedPubMedCentral

19.

Varga Z, Lebeau A, Bu H, Hartmann A, Penault-Llorca F, Guerini-Rocco E et al (2017) An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®. Breast Cancer Res 19(1):55. https://doi.org/10.1186/s13058-017-0848-zCrossRefPubMedPubMedCentral

20.

Balduzzi A, Bagnardi V, Rotmensz N, Dellapasqua S, Montagna E, Cardillo A et al (2014) Survival outcomes in breast cancer patients with low estrogen/progesterone receptor expression. Clin Breast Cancer 14(4):258–264. https://doi.org/10.1016/j.clbc.2013.10.019CrossRefPubMed

21.

Prat A, Cheang MC, Martín M, Parker JS, Carrasco E, Caballero R et al (2013) Prognostic significance of progesterone receptor-positive tumor cells within immunohistochemically defined luminal A breast cancer. J Clin Oncol 31(2):203–209. https://doi.org/10.1200/jco.2012.43.4134CrossRefPubMed

22.

Li AQ, Zhou SL, Li M, Xu Y, Shui RH, Yu BH et al (2015) Clinicopathologic characteristics of oestrogen receptor-positive/progesterone receptor-negative/Her2-negative breast cancer according to a novel definition of negative progesterone receptor status: a large population-based study from China. PLoS ONE 10(5):e0125067. https://doi.org/10.1371/journal.pone.0125067CrossRefPubMedPubMedCentral

23.

Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K et al (2017) Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol 18(11):1512–1522. https://doi.org/10.1016/s1470-2045(17)30604-6CrossRefPubMed

24.

Tarantino P, Hamilton E, Tolaney SM, Cortes J, Morganti S, Ferraro E et al (2020) HER2-low breast cancer: pathological and clinical landscape. J Clin Oncol 38(17):1951–1962. https://doi.org/10.1200/jco.19.02488CrossRefPubMed

25.

de Azambuja E, Cardoso F, de Castro Jr. G, Colozza M, Mano MS, Durbecq V et al (2007) Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients. Br J Cancer 96(10):1504–1513. https://doi.org/10.1038/sj.bjc.6603756CrossRefPubMedPubMedCentral

26.

Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thürlimann B, Senn HJ (2011) Strategies for subtypes–dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the primary therapy of early breast cancer 2011. Ann Oncol 22(8):1736–1747. https://doi.org/10.1093/annonc/mdr304CrossRefPubMedPubMedCentral

27.

Polley MY, Leung SC, Gao D, Mastropasqua MG, Zabaglo LA, Bartlett JM et al (2015) An international study to increase concordance in Ki67 scoring. Mod Pathol 28(6):778–786. https://doi.org/10.1038/modpathol.2015.38CrossRefPubMed

28.

Leung SCY, Nielsen TO, Zabaglo LA, Arun I, Badve SS, Bane AL et al (2019) Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration. Histopathology 75(2):225–235. https://doi.org/10.1111/his.13880CrossRefPubMed

29.

Janeva S, Parris TZ, Nasic S, De Lara S, Larsson K, Audisio RA et al (2021) Comparison of breast cancer surrogate subtyping using a closed-system RT-qPCR breast cancer assay and immunohistochemistry on 100 core needle biopsies with matching surgical specimens. BMC Cancer 21(1):439. https://doi.org/10.1186/s12885-021-08171-2CrossRefPubMedPubMedCentral

Titel: Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer
verfasst von: Lili Chen
Yanyang Chen
Zhongpeng Xie
Jiao Luo
Yuefeng Wang
Jianwen Zhou
Leilei Huang
Hongxia Li
Linhai Wang
Pei Liu
Man Shu
Wenhui Zhang
Zunfu Ke
Publikationsdatum: 05.07.2022
Verlag: Springer US
Erschienen in: Breast Cancer Research and Treatment / Ausgabe 3/2022
Print ISSN: 0167-6806
Elektronische ISSN: 1573-7217
DOI: https://doi.org/10.1007/s10549-022-06649-6

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Comparison of immunohistochemistry and RT-qPCR for assessing ER, PR, HER2, and Ki67 and evaluating subtypes in patients with breast cancer